Clinical trial · Interventional
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma
NCT00003737CI-TRIAL-00011035completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| becatecarin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Response (complete response, very good partial response, or partial response)
- measure
- Freedom from progression
- measure
- Time to treatment failure
Secondary outcomes (1)
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven relapsed or refractory neuroblastoma * Measurable disease PATIENT CHARACTERISTICS: Age: * Children Performance status: * ECOG 0-2 Life expectancy: * At least 2 months Hematopoietic: * Not specified Hepatic: * Bilirubin less than 1.5 mg/dL * SGOT and SGPT less than 2.5 times upper limit of normal (ULN) * Adequate liver function unless due to disease Renal: * Creatinine no greater than 1.5 times ULN OR * Creatinine clearance at least 60 mL/min * Adequate renal function unless due to disease Other: * No other serious concurrent illness * No active uncontrolled infection * Not pregnant * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Recovered from prior immunotherapy * Prior autologous bone marrow transplantation allowed * No concurrent immunotherapy Chemotherapy: * At least 4 weeks since prior chemotherapy and recovered * No other concurrent systemic chemotherapy Endocrine therapy: * Not specified Radiotherapy: * Recovered from prior radiotherapy Surgery: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.